Lepu Biopharma Co., Ltd.
Registry sponsor category
Industry
- Other names
- Lepu Biopharma Co., Ltd.
- Company name
- Lepu Biopharma Co., Ltd.
- Organisation type
- Industry
- Registry sponsor category
- Industry
- Publicly traded (proxy)
- No
- Listing at source
- Listed
Related records
Trials (21)
- A Single-Arm Phase II Clinical Study of Docetaxel Combined With Nimotuzumab and Pucotenlimab as Second-Line and Beyond Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer
- A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
- A Study of MRG003 in Patients With Advanced Solid Tumors
- A Study of MRG003 in the Treatment of EGFR-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer
- A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors
- A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors
- A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors
- A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
- A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer
- A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN
- A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.
- A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer
- A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma
- A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
- MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
- Neoadjuvant Presurgical Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Oral Cavity Squamous Cell Carcinoma
- Phase II Study of Becotatug Vedotin Plus Pucotenlimab for Advanced Refractory Solid Tumors With EGFR-Positive
- Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell Carcinoma
- Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma